Diabetes, metformin and incidence of and death from invasive cancer in postmenopausal women: Results from the women's health initiative

International Journal of Cancer

Volumn 138, Issue 8, 2016, Pages 1915-1927

  Gong, Zhihong ^a   Aragaki, Aaron K ^b   Chlebowski, Rowan T ^c   Manson, Joann E ^d   Rohan, Thomas E ^e   Chen, Chu ^b   Vitolins, Mara Z ^f   Tinker, Lesley F ^b   Leblanc, Erin S ^g   Kuller, Lewis H ^h   Hou, Lifang ⁱ   Lamonte, Michael J ^j   Luo, Juhua ^k   Wactawski Wende, Jean ^j  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b USA   (United States)

^c HARBOR UCLA MEDICAL CENTER   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^f WAKE FOREST SCHOOL OF MEDICINE   (United States)

^g CENTER FOR HEALTH RESEARCH   (United States)

^h UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

ⁱ NORTHWESTERN UNIVERSITY   (United States)

^j UNIVERSITY AT BUFFALO   (United States)

^k INDIANA UNIVERSITY   (United States)

more..

Author keywords

diabetes; incidence; invasive cancer; metformin; mortality

Indexed keywords

METFORMIN; ANTIDIABETIC AGENT;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HUMAN; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; TREATMENT DURATION; INCIDENCE; MIDDLE AGED; NEOPLASMS; PROPORTIONAL HAZARDS MODEL;

AGED; DIABETES MELLITUS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; METFORMIN; MIDDLE AGED; NEOPLASMS; POSTMENOPAUSE; PROPORTIONAL HAZARDS MODELS;

EID: 84958889686     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29944     Document Type: Article

References (47)

1. Noto H, Tsujimoto T, Sasazuki T, et al., Significantly increased risk of cancer in patients with diabetes mellitus: A systematic review and meta-analysis. Endocr Pract 2011; 17: 616-28.
2. Joshi S, Liu M, Turner N., Diabetes and its link with cancer: providing the fuel and spark to launch an aggressive growth regime. Biomed Res Int 2015; 2015: 390863
3. Samani AA, Yakar S, LeRoith D, et al., The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 2007; 28: 20-47.
4. Viollet B, Guigas B, Sanz Garcia N, et al., Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond) 2012; 122: 253-70.
5. Decensi A, Puntoni M, Goodwin P, et al., Metformin and cancer risk in diabetic patients: A systematic review and meta-analysis. Cancer Prev Res (Phila) 2010; 3: 1451-61.
6. Maccio A, Madeddu C., Obesity, inflammation, and postmenopausal breast cancer: therapeutic implications. Sci J 2011; 11: 2020-36.
7. Women's Health Initiative Study Group. Design of the women's health initiative clinical trial and observational study. Control Clin Trials 1998; 19: 61-109.
8. Anderson GL, Manson J, Wallace R, et al., Implementation of the women's health initiative study design. Ann Epidemiol 2003; 13: S5-17.
9. Hays J, Hunt JR, Hubbell FA, et al., The women's health initiative recruitment methods and results. Ann Epidemiol 2003; 13: S18-77.
10. Margolis KL, Lihong Q, Brzyski R, et al., Validity of diabetes self-reports in the Women's Health Initiative: comparison with medication inventories and fasting glucose measurements. Clin Trials 2008; 5: 240-47.
11. Chlebowski RT, McTiernan A, Wactawski-Wende J, et al., Diabetes, metformin, and breast cancer in postmenopausal women. J Clin Oncol 2012; 30: 2844-52.
12. Curb JD, McTiernan A, Heckbert SR, et al., Outcomes ascertainment and adjudication methods in the women's health initiative. Ann Epidemiol 2003; 13: S122.
13. Bodmer M, Meier C, Krähenbühl S, et al., Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care 2010; 33: 1304-8.
14. Wang C, Wang X, Gong G, et al., Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies. Int J Cancer 2012; 130: 1639-48.
15. Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A, et al., Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 2005; 92: 2076-83.
16. Jiang Y, Ben Q, Shen H, et al., Diabetes mellitus and incidence and mortality of colorectal cancer: a systematic review and meta-analysis of cohort studies. Eur J Epidemiol 2011; 26: 863-76.
17. Kramer HU, Schottker B, Raum E, et al., Type 2 diabetes mellitus and colorectal cancer: meta-analysis on sex-specific differences. Eur J Cancer 2012; 48: 1269-82.
18. Mitri J, Castillo J, Pittas AG., Diabetes and risk of non-hodgkin's lymphoma: A meta-analysis of observational studies. Diabetes Care 2008; 31: 2391-97.
19. Zhang ZH, Su PY, Hao JH, Sun YH., The role of preexisting diabetes mellitus on incidence and mortality of endometrial cancer: a meta-analysis of prospective cohort studies. Int J Gynecol Cancer 2013; 23: 294-303.
20. Giovannucci E, Harlan DM, Archer MC, et al., Diabetes and cancer: A consensus report. Diabetes Care 2010; 33: 1674-85.
21. Gallagher EJ, LeRoith D., Minireview: IGF, insulin, and cancer. Endocrinology 2011; 152: 2546-51.
22. Col NF, Ochs L, Springmann V, et al., Metformin and breast cancer risk: a meta-analysis and critical literature review. Breast Cancer Res Treat 2012; 135: 639-46.
23. La Vecchia C, Giordano SH, Hortobagyi GN, et al., Overweight, obesity, diabetes, and risk of breast cancer: interlocking pieces of the puzzle. Oncologist 2011; 16: 726-29.
24. Ligibel J., Obesity and breast cancer. Oncology (Williston Park) 2011; 25: 994-1000.
25. Currie CJ, Poole CD, Gale EA., The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009; 52: 1766-77.
26. Libby G, Donnelly LA, Donnan PT, et al., New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 2009; 32: 1620-25.
27. Monami M, Colombi C, Balzi D, et al., Metformin and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care 2011; 34: 129-31.
28. Franciosi M, Lucisano G, Lapice E, et al., Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS One 2013; 8: e71583.
29. Stevens RJ, Ali R, Bankhead CR, et al., Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials. Diabetologia 2012; 55: 2593-603.
30. Suissa S, Azoulay L., Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care 2012; 35: 2665-73.
31. Srinivasan S, Ambler GR, Baur LA, et al., Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. J Clin Endocrinol Metab 2006; 91: 2074-80.
32. Yanovski JA, Krakoff J, Salaita CG, et al., Effects of metformin on body weight and body composition in obese insulin-resistant children: a randomized clinical trial. Diabetes 2011; 60: 477-85.
33. Kalender A, Selvaraj A, Kim SY, et al., Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab 2010; 11: 390-401.
34. Suissa S, Azoulay L., Metformin and cancer: mounting evidence against an association. Diabetes Care 2014; 37: 1786-88.
35. Azoulay L, Dell'Aniello S, Gagnon B, et al., Metformin and the incidence of prostate cancer in patients with type 2 diabetes. Cancer Epidemiol Biomarkers Prev 2011; 20: 337-44.
36. Smiechowski BB, Azoulay L, Yin H, et al., The use of metformin and the incidence of lung cancer in patients with type 2 diabetes. Diabetes Care 2013; 36: 124-29.
37. Mamtani R, Pfanzelter N, Haynes K, et al., Incidence of bladder cancer in patients with type 2 diabetes treated with metformin or sulfonylureas. Diabetes Care 2014; 37: 1910-17.
38. Larsson SC, Orsini N, Wolk A., Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst 2005; 97: 1679-87.
39. Bowker SL, Majumdar SR, Veugelers P, et al., Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006; 29: 254-58.
40. Landman GW, Kleefstra N, van Hateren KJ, et al., Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care 2010; 33: 322-26.
41. Currie CJ, Poole CD, Jenkins-Jones S, et al., Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes Care 2012; 35: 299-304.
42. Zhang P, Li H, Tan X, et al., Association of metformin use with cancer incidence and mortality: a meta-analysis. Cancer Epidemiol 2013; 37: 207-18.
43. Kumar S, Meuter A, Thapa P, et al., Metformin intake is associated with better survival in ovarian cancer: a case-control study. Cancer 2013; 119: 555-62.
44. Nevadunsky NS, Van Arsdale A, Strickler HD, et al., Metformin use and endometrial cancer survival. Gynecol Oncol 2014; 132: 236-40.
45. Cossor FI, Adams-Campbell LL, Chlebowski RT, et al., Diabetes, metformin use, and colorectal cancer survival in postmenopausal women. Cancer Epidemiol 2013; 37: 742-49.
46. Peeters PJ, Bazelier MT, Vestergaard P, et al., Use of metformin and survival of diabetic women with breast cancer. Curr Drug Saf 2013; 8: 357-63.
47. Yin M, Zhou J, Gorak EJ, et al., Metformin is associated with survival benefit in cancer patients with concurrent type 2 diabetes: a systematic review and meta-analysis. Oncologist 2013; 18: 1248-55.